Trial reportCancer2017
Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis.
Trial report in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2019Guideline
- Cancer survivorship care for young adults: a risk-stratified, multicenter randomized controlled trial to improve symptoms.Journal of cancer survivorship : research and practice · 2022Trial
- Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors.Transplantation and cellular therapy · 2022Trial
- Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors.Haematologica · 2019Trial
- Rates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018Trial
- An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation.Journal of cancer survivorship : research and practice · 2018Trial
- INteractive survivorship program to improve health care REsources [INSPIRE]: A study protocol testing a digital intervention with stepped care telehealth to improve outcomes for adolescent and young adult survivors.Contemporary clinical trials · 2025Article
- Article
- Social Support, Coping, and Cancer-Related Health Burden in Long-term Survivors Treated with Hematopoietic Stem Cell Transplantation as Adolescents or Young Adults.Journal of adolescent and young adult oncology · 2023Article
- Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.Transplantation and cellular therapy · 2023Article
- Pre-Surgery Inflammatory and Angiogenesis Biomarkers as Predictors of 12-Month Cancer-Related Distress: Results from the ColoCare Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
- Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.Transplantation and cellular therapy · 2023Article
- Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2022Article
- Fatigue among post-hematopoietic stem cell transplant patients in Jordan: prevalence and associated factors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Biobehavioral Implications of Covid-19 for Transplantation and Cellular Therapy Recipients.Frontiers in immunology · 2022Review
- Biobehavioral Research and Hematopoietic Stem Cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and Cellular Therapy.Transplantation and cellular therapy · 2021Review
- Free of malignancy but not of fears: A closer look at Damocles syndrome in survivors of hematologic malignancies.Blood reviews · 2021Review
- Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase.JCO oncology practice · 2021Review
- Sexual Functioning in Long-Term Survivors of Hematopoietic Cell Transplantation.Transplantation and cellular therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundRoutine monitoring of cancer-related distress is recognized as essential to quality care and mandated by a major accrediting organization. However, to the authors' knowledge, few cancer-specific measures have been developed to date to assess the multiple cancer-related factors contributing to this distress. In the current study, the authors examined the psychometric properties of the Cancer and Treatment Distress (CTXD) measure over time in hematopoietic cell transplantation (HCT) recipients.
methodsAs a secondary analysis of a multicenter randomized controlled clinical trial, adult patients undergoing autologous or allogeneic HCT completed patient-reported outcomes including the CTXD and the Medical Outcomes Study Short Form-36 (SF-36) before transplantation and 100 days and 180 days after HCT.
resultsAcross 21 transplantation centers, a total of 701 patients consented, underwent transplantation, and were included in the current analyses, 645 of whom were alive at 100 days and 618 of whom were alive at 180 days. Internal consistency reliability was found to be strong for the overall CTXD at the 3 time points: Cronbach alphas (α) were .94, .95, and .95, respectively. Subscale reliability met hypothesized levels of an α>.70 across time, with the lowest reliability noted for the Identity subscale at 180 days (α = .77). Correlations with the SF-36 Mental Health subscale were higher than with the Physical Functioning subscale at each time point, thereby supporting convergent and discriminant validity. Strong correlations of the pretransplantation CTXD with the posttransplantation CTXD and SF-36 Mental Health subscale supported predictive validity.
conclusionsThe CTXD is reliable and valid as a measure of cancer distress both before and after HCT. It may be a useful tool for measuring dimensions of distress and for defining those patients requiring treatment for distress during and after transplantation. Cancer 2017;123:1416-1423. © 2016 American Cancer Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.